{"success":true,"data":{"pressRelease":{"id":"155159","rtpr_id":"nNFC4SQCxR-20260929","ticker":"KALA","exchange":"NASDAQ","all_tickers":["KALA"],"title":"KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception","author":"Newsfile Corp","published_at":"2026-09-29T11:30:15.127Z","article_body":"Proposed Acquisition Valued at Approximately $15 Million Would Add an\nEstablished 50-State Telehealth Business, with over 90,000 clients, Focused on\nPeptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual\nWellness\n\nKey Highlights\n*\nTarget generated approximately $12.7 million in revenue for the trailing\ntwelve months ended August 2026 (unaudited, as provided by Target management)\nand is cash-flow positive\n*\nProposed purchase price of approximately $15 million, payable in cash and KALA\nstock; the cash portion is expected to be funded from existing balance sheet\nresources\n*\nFounded in 2023; LegitScript-certified, NABP-accredited platform serving\nclients in all 50 states; more than 90,000 clients served since inception\n*\n45-day due diligence period expected to conclude in November 2026; definitive\nagreements and closing targeted for late 2026 or early 2027\n\nNew York, New York--(Newsfile Corp. - September 29, 2026) - KALA Bio, Inc.\n(NASDAQ: KALA) (\"KALA\" or the \"Company\") today announced that on September 24,\n2026, it signed a non-binding letter of intent (\"LOI\") for the proposed\nacquisition of 100% of a privately held, U.S.-based management services\norganization (\"MSO\") supporting a LegitScript-certified, NABP-accredited\nprovider-led telehealth platform serving clients in all 50 states (the\n\"Target\"). Based on unaudited financial information provided by the Target's\nmanagement, the Target generated approximately $12.7 million in revenue for\nthe trailing twelve months ended August 2026.\n\nThe Target's platform connects clients with U.S.-licensed providers for online\nconsultations, with prescribed therapies dispensed through verified pharmacies\nand delivered to the home. Its core business is selling health and wellness\ntherapies across weight management, including GLP-1 therapies, hormone health,\nlongevity, and sexual wellness, supported by at-home lab testing and\nAI-assisted client engagement tools. Since its founding in 2023, The Target\nhas served more than 90,000 clients and generated over $48 million in sales.\nThe Target's GLP-1 therapies are compounded medications prescribed by licensed\nproviders and dispensed by licensed, FDA-approved compounding pharmacies. The\nTarget is built on AI and runs efficiently, and we believe it will be highly\nscalable. The Target's underlying native AI infrastructure aligns with KALA's\ndevelopment of Researgency.ai, and KALA intends to evaluate integrating its\ncapabilities into further AI development following closing. The Target would\nprovide KALA with an established, revenue-generating platform for long-term\nclient health management and a direct-to-consumer channel for the Company's\npreventative care initiatives, including genetic testing products distributed\nunder KALA's agreement with Virotek.\n\nThe contemplated transaction is valued at approximately $15 million, payable\nin a combination of cash and KALA stock. KALA expects to fund the cash portion\nof the consideration from existing balance sheet resources. Any issuance of\nKALA common stock in connection with the transaction is expected to be subject\nto approvals and to the Nasdaq Listing Rules. The final allocation between\ncash and stock will be determined during diligence and announced upon\nexecution of definitive agreements. The Target's existing management team is\nexpected to continue operating the business following closing.\n\n\"This transaction would add an established, revenue-generating platform to\nKALA's operating business, alongside our Virotek distribution program, with a\ndirect channel to clients focused on preventative care and long-term health\nmanagement,\" said Avi Minkowitz, Chief Executive Officer and Chief Financial\nOfficer of KALA. \"We expect the Target's established revenue base to benefit\nKALA's growth in this business and across our other lines of business. With\nmore than 90,000 clients served since 2023, we see opportunities to grow the\nbusiness, including by offering Virotek genetic testing through the platform\nand by exploring additional offerings. We look forward to completing diligence\nand moving to definitive agreements. We are targeting closing in late 2026 or\nearly 2027.\"\n\nThe LOI provides for a 45-day due diligence period (with possible extensions),\nexpected to conclude in November 2026. The financial information in this\nrelease is unaudited, was provided by the Target, and has not been\nindependently verified by KALA. Investors should not place undue reliance on\nit.\n\nThe proposed transaction is subject to:\n*\nsatisfactory completion of due diligence, including an audit of the Target's\nfinancial statements;\n*\nnegotiation and execution of definitive agreements;\n*\nreceipt of required corporate, regulatory and stock exchange approvals\n(including KALA stockholder approval, if required), including the transfer of\napplicable pharmacy and healthcare licenses; and\n*\nother customary closing conditions.\n\nThere can be no assurance that definitive agreements will be executed or that\nthe proposed transaction will be completed on the terms described, or at all.\nThe Company expects to provide further updates upon completion of due\ndiligence and execution of definitive agreements, or when further disclosure\nis otherwise deemed appropriate.\n\nAbout KALA Bio, Inc.\n\nKALA BIO, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company\nbuilding a dedicated, on-premises AI infrastructure platform for the\nbiotechnology industry. The Company's dual strategy combines a proprietary\nbiologics pipeline—including its mesenchymal stem cell secretome (MSC-S)\nplatform and FDA Orphan Drug- and Fast Track-designated product\ncandidates—with a scalable AI platform-as-a-service business designed to\ndeploy secure, purpose-built AI solutions directly within biotech and\npharmaceutical client environments. KALA also holds exclusive U.S.\ndistribution rights for Virotek's ophthalmology genetic testing program and is\nevaluating acquisitions of revenue-generating healthcare businesses.\n\nThrough its exclusive worldwide license for the Researgency AI research\nplatform from Younet, KALA intends to serve as the dedicated AI infrastructure\npartner for the biotechnology industry, enabling organizations of all sizes to\nunlock the value of their proprietary biological data without surrendering\ncontrol. KALA is advancing an agentic transformation strategy for biomedical\norganizations through Researgency.ai, a platform designed to enable scalable,\ngoverned deployment of AI agents across research, documentation, and\noperational workflows.\n\nFor more information, visit www.kalarx.com and Researgency.ai\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the proposed acquisition of the Target; the expected timing of the\ncompletion of due diligence, the execution of definitive agreements and the\nclosing of the proposed transaction; the expected consideration and its\nallocation between cash and stock; the Company's expected sources of funding\nfor the cash portion of the consideration; any required stockholder,\nregulatory or stock exchange approvals; the expected benefits of the proposed\ntransaction, including the Target's revenue base and its expected contribution\nto the Company's growth; opportunities to grow the Target's business,\nincluding by offering Virotek genetic testing products through the Target's\nplatform and by exploring additional offerings; the potential integration of\nthe Target's AI capabilities with the Researgency platform; the expected\ncontinuation of the Target's management team following closing; the Company's\nstrategic initiative to build an AI infrastructure platform for the\nbiotechnology industry; and other statements that are not historical facts.\n\nThe Company uses words like \"anticipate,\" \"believe,\" \"continue,\" \"could,\"\n\"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\"\n\"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" \"would\" and similar\nexpressions to identify these forward-looking statements. These statements\ninvolve known and unknown risks, uncertainties, and other factors which may\ncause actual results, performance, or achievements to be materially different\nfrom those expressed or implied by such statements. Important factors that\ncould cause such differences include, but are not limited to: the risk that\nthe Company does not complete due diligence or execute definitive agreements\non the terms described or at all, or that the proposed transaction does not\nclose on the expected timeline or at all; the availability of balance sheet\nresources to fund the cash portion of the consideration, including the timely\ncollection of short-term investments; dilution to existing stockholders from\nthe stock consideration, and the risk that any required stockholder approval\nis not obtained; reliance on unaudited financial information provided by the\nTarget, which has not been independently verified and may differ from audited\nresults; risks related to FDA, state pharmacy board and other regulatory\nenforcement relating to compounded GLP-1 and other compounded products,\nincluding potential loss of supply under Sections 503A and 503B of the Federal\nFood, Drug, and Cosmetic Act; potential litigation by manufacturers of branded\nGLP-1 products; risks related to corporate-practice-of-medicine laws and the\nTarget's MSO structure; the potential loss of LegitScript certification or\nNABP accreditation; risks related to the transfer of pharmacy and healthcare\nlicenses; risks related to integrating the Target's business and retaining its\nmanagement team; risks related to the Company's distribution program with\nVirotek; risks related to the development, deployment, and performance of the\nReseargency platform and the Company's ability to attract and retain platform\nclients; risks that the Company's product candidates may not be successfully\ndeveloped or commercialized; risks related to the Company's limited cash\nresources and ability to continue as a going concern; risks related to the\nCompany's ability to raise future capital on favorable terms or at all; risks\nrelated to the Company's ability to regain compliance with Nasdaq listing\nrequirements and maintain its listing; competition from larger,\nbetter-resourced companies; dependence on key personnel and third-party\ntechnology providers; and other risks detailed in the \"Risk Factors\" section\nof the Company's Annual Report on Form 10-K as they may be revised in the\nCompany's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and\nother filings with the Securities and Exchange Commission.\n\nForward-looking statements speak only as of the date of this release, and the\nCompany undertakes no obligation to publicly update or revise any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as required by law.\n\nContact:\n\nAvi Minkowitz\nChief Executive Officer, KALA BIO, Inc.\nam@kalarx.com\nwww.kalarx.com | www.Researgency.ai\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316479","article_body_html":"","raw_payload":{"data":{"id":"nNFC4SQCxR-20260929","title":"KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception","author":"Newsfile Corp","ticker":"KALA","created":"2026-09-29T11:30:15.127Z","tickers":["KALA"],"exchange":"NASDAQ","article_body":"Proposed Acquisition Valued at Approximately $15 Million Would Add an\nEstablished 50-State Telehealth Business, with over 90,000 clients, Focused on\nPeptides such as GLP-1 Weight Management, Hormone Health, Longevity and Sexual\nWellness\n\nKey Highlights\n*\nTarget generated approximately $12.7 million in revenue for the trailing\ntwelve months ended August 2026 (unaudited, as provided by Target management)\nand is cash-flow positive\n*\nProposed purchase price of approximately $15 million, payable in cash and KALA\nstock; the cash portion is expected to be funded from existing balance sheet\nresources\n*\nFounded in 2023; LegitScript-certified, NABP-accredited platform serving\nclients in all 50 states; more than 90,000 clients served since inception\n*\n45-day due diligence period expected to conclude in November 2026; definitive\nagreements and closing targeted for late 2026 or early 2027\n\nNew York, New York--(Newsfile Corp. - September 29, 2026) - KALA Bio, Inc.\n(NASDAQ: KALA) (\"KALA\" or the \"Company\") today announced that on September 24,\n2026, it signed a non-binding letter of intent (\"LOI\") for the proposed\nacquisition of 100% of a privately held, U.S.-based management services\norganization (\"MSO\") supporting a LegitScript-certified, NABP-accredited\nprovider-led telehealth platform serving clients in all 50 states (the\n\"Target\"). Based on unaudited financial information provided by the Target's\nmanagement, the Target generated approximately $12.7 million in revenue for\nthe trailing twelve months ended August 2026.\n\nThe Target's platform connects clients with U.S.-licensed providers for online\nconsultations, with prescribed therapies dispensed through verified pharmacies\nand delivered to the home. Its core business is selling health and wellness\ntherapies across weight management, including GLP-1 therapies, hormone health,\nlongevity, and sexual wellness, supported by at-home lab testing and\nAI-assisted client engagement tools. Since its founding in 2023, The Target\nhas served more than 90,000 clients and generated over $48 million in sales.\nThe Target's GLP-1 therapies are compounded medications prescribed by licensed\nproviders and dispensed by licensed, FDA-approved compounding pharmacies. The\nTarget is built on AI and runs efficiently, and we believe it will be highly\nscalable. The Target's underlying native AI infrastructure aligns with KALA's\ndevelopment of Researgency.ai, and KALA intends to evaluate integrating its\ncapabilities into further AI development following closing. The Target would\nprovide KALA with an established, revenue-generating platform for long-term\nclient health management and a direct-to-consumer channel for the Company's\npreventative care initiatives, including genetic testing products distributed\nunder KALA's agreement with Virotek.\n\nThe contemplated transaction is valued at approximately $15 million, payable\nin a combination of cash and KALA stock. KALA expects to fund the cash portion\nof the consideration from existing balance sheet resources. Any issuance of\nKALA common stock in connection with the transaction is expected to be subject\nto approvals and to the Nasdaq Listing Rules. The final allocation between\ncash and stock will be determined during diligence and announced upon\nexecution of definitive agreements. The Target's existing management team is\nexpected to continue operating the business following closing.\n\n\"This transaction would add an established, revenue-generating platform to\nKALA's operating business, alongside our Virotek distribution program, with a\ndirect channel to clients focused on preventative care and long-term health\nmanagement,\" said Avi Minkowitz, Chief Executive Officer and Chief Financial\nOfficer of KALA. \"We expect the Target's established revenue base to benefit\nKALA's growth in this business and across our other lines of business. With\nmore than 90,000 clients served since 2023, we see opportunities to grow the\nbusiness, including by offering Virotek genetic testing through the platform\nand by exploring additional offerings. We look forward to completing diligence\nand moving to definitive agreements. We are targeting closing in late 2026 or\nearly 2027.\"\n\nThe LOI provides for a 45-day due diligence period (with possible extensions),\nexpected to conclude in November 2026. The financial information in this\nrelease is unaudited, was provided by the Target, and has not been\nindependently verified by KALA. Investors should not place undue reliance on\nit.\n\nThe proposed transaction is subject to:\n*\nsatisfactory completion of due diligence, including an audit of the Target's\nfinancial statements;\n*\nnegotiation and execution of definitive agreements;\n*\nreceipt of required corporate, regulatory and stock exchange approvals\n(including KALA stockholder approval, if required), including the transfer of\napplicable pharmacy and healthcare licenses; and\n*\nother customary closing conditions.\n\nThere can be no assurance that definitive agreements will be executed or that\nthe proposed transaction will be completed on the terms described, or at all.\nThe Company expects to provide further updates upon completion of due\ndiligence and execution of definitive agreements, or when further disclosure\nis otherwise deemed appropriate.\n\nAbout KALA Bio, Inc.\n\nKALA BIO, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company\nbuilding a dedicated, on-premises AI infrastructure platform for the\nbiotechnology industry. The Company's dual strategy combines a proprietary\nbiologics pipeline—including its mesenchymal stem cell secretome (MSC-S)\nplatform and FDA Orphan Drug- and Fast Track-designated product\ncandidates—with a scalable AI platform-as-a-service business designed to\ndeploy secure, purpose-built AI solutions directly within biotech and\npharmaceutical client environments. KALA also holds exclusive U.S.\ndistribution rights for Virotek's ophthalmology genetic testing program and is\nevaluating acquisitions of revenue-generating healthcare businesses.\n\nThrough its exclusive worldwide license for the Researgency AI research\nplatform from Younet, KALA intends to serve as the dedicated AI infrastructure\npartner for the biotechnology industry, enabling organizations of all sizes to\nunlock the value of their proprietary biological data without surrendering\ncontrol. KALA is advancing an agentic transformation strategy for biomedical\norganizations through Researgency.ai, a platform designed to enable scalable,\ngoverned deployment of AI agents across research, documentation, and\noperational workflows.\n\nFor more information, visit www.kalarx.com and Researgency.ai\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\nthe Private Securities Litigation Reform Act of 1995, including statements\nregarding the proposed acquisition of the Target; the expected timing of the\ncompletion of due diligence, the execution of definitive agreements and the\nclosing of the proposed transaction; the expected consideration and its\nallocation between cash and stock; the Company's expected sources of funding\nfor the cash portion of the consideration; any required stockholder,\nregulatory or stock exchange approvals; the expected benefits of the proposed\ntransaction, including the Target's revenue base and its expected contribution\nto the Company's growth; opportunities to grow the Target's business,\nincluding by offering Virotek genetic testing products through the Target's\nplatform and by exploring additional offerings; the potential integration of\nthe Target's AI capabilities with the Researgency platform; the expected\ncontinuation of the Target's management team following closing; the Company's\nstrategic initiative to build an AI infrastructure platform for the\nbiotechnology industry; and other statements that are not historical facts.\n\nThe Company uses words like \"anticipate,\" \"believe,\" \"continue,\" \"could,\"\n\"estimate,\" \"expect,\" \"intend,\" \"may,\" \"might,\" \"plan,\" \"potential,\"\n\"predict,\" \"project,\" \"should,\" \"target,\" \"will,\" \"would\" and similar\nexpressions to identify these forward-looking statements. These statements\ninvolve known and unknown risks, uncertainties, and other factors which may\ncause actual results, performance, or achievements to be materially different\nfrom those expressed or implied by such statements. Important factors that\ncould cause such differences include, but are not limited to: the risk that\nthe Company does not complete due diligence or execute definitive agreements\non the terms described or at all, or that the proposed transaction does not\nclose on the expected timeline or at all; the availability of balance sheet\nresources to fund the cash portion of the consideration, including the timely\ncollection of short-term investments; dilution to existing stockholders from\nthe stock consideration, and the risk that any required stockholder approval\nis not obtained; reliance on unaudited financial information provided by the\nTarget, which has not been independently verified and may differ from audited\nresults; risks related to FDA, state pharmacy board and other regulatory\nenforcement relating to compounded GLP-1 and other compounded products,\nincluding potential loss of supply under Sections 503A and 503B of the Federal\nFood, Drug, and Cosmetic Act; potential litigation by manufacturers of branded\nGLP-1 products; risks related to corporate-practice-of-medicine laws and the\nTarget's MSO structure; the potential loss of LegitScript certification or\nNABP accreditation; risks related to the transfer of pharmacy and healthcare\nlicenses; risks related to integrating the Target's business and retaining its\nmanagement team; risks related to the Company's distribution program with\nVirotek; risks related to the development, deployment, and performance of the\nReseargency platform and the Company's ability to attract and retain platform\nclients; risks that the Company's product candidates may not be successfully\ndeveloped or commercialized; risks related to the Company's limited cash\nresources and ability to continue as a going concern; risks related to the\nCompany's ability to raise future capital on favorable terms or at all; risks\nrelated to the Company's ability to regain compliance with Nasdaq listing\nrequirements and maintain its listing; competition from larger,\nbetter-resourced companies; dependence on key personnel and third-party\ntechnology providers; and other risks detailed in the \"Risk Factors\" section\nof the Company's Annual Report on Form 10-K as they may be revised in the\nCompany's Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and\nother filings with the Securities and Exchange Commission.\n\nForward-looking statements speak only as of the date of this release, and the\nCompany undertakes no obligation to publicly update or revise any\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as required by law.\n\nContact:\n\nAvi Minkowitz\nChief Executive Officer, KALA BIO, Inc.\nam@kalarx.com\nwww.kalarx.com | www.Researgency.ai\n\n\nTo view the source version of this press release, please visit\nhttps://www.newsfilecorp.com/release/316479"},"type":"article","timestamp":"2026-09-29T11:30:15.18681349Z","server_sent_at_ms":1790681415186},"received_at":"2026-09-29T11:30:15.272Z","source_url":"https://www.newsfilecorp.com/release/316479"},"analysis":{"id":"143901","press_release_id":"155159","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["LOI is non-binding; no assurance definitive agreements will be executed","Target financials are unaudited and provided by Target management without independent verification","Stock consideration may dilute existing holders and requires Nasdaq Listing Rule approvals and possible stockholder vote","Reliance on compounded GLP-1 products carries FDA/regulatory enforcement risk (503A/503B) and branded-manufacturer litigation risk","Company discloses limited cash resources and going-concern risk; Nasdaq listing compliance risk"],"eventType":"m_and_a","narrative":"KALA Bio signed a non-binding LOI to acquire 100% of a U.S.-based MSO supporting a 50-state telehealth platform for approximately $15 million in cash and stock.\n\nThe Target generated about $12.7 million in trailing-twelve-month revenue through August 2026, is cash-flow positive, and has served more than 90,000 clients since 2023, focused on GLP-1 weight management, hormone health, longevity and sexual wellness.\n\nA 45-day diligence period concludes in November 2026, with definitive agreements and closing targeted for late 2026 or early 2027; the deal faces stockholder, Nasdaq and pharmacy-license approvals.\n\nKALA sees the Target as a direct-to-consumer channel for its Virotek genetic testing and a fit with its Researgency.ai platform, but the Target's financials are unaudited and management-provided.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Tiny biotech pivots further into telehealth/AI with a $15M revenue-generating acquisition -- watch diligence outcome and dilution terms."},"keyFigures":{"dealValueUsd":"$15 million","customDimensions":{"target_founded":"2023","target_ttm_revenue":"$12.7 million (TTM ended August 2026, unaudited)","due_diligence_period":"45 days, expected to conclude November 2026","target_clients_served":"more than 90,000","target_sales_since_inception":"over $48 million"}},"quotedText":"This transaction would add an established, revenue-generating platform to KALA's operating business, alongside our Virotek distribution program, with a direct channel to clients focused on preventative care and long-term health management","namedEntities":{"people":[{"name":"Avi Minkowitz","role":"CEO and CFO of KALA Bio"}],"products":["Researgency.ai","GLP-1 compounded therapies","Virotek ophthalmology genetic testing","MSC-S platform"],"companies":[{"name":"KALA Bio, Inc.","ticker":"KALA","relationship":"acquirer"},{"name":"Virotek","relationship":"distribution partner"},{"name":"Younet","relationship":"licensor of Researgency AI platform"}],"dollarAmounts":[{"amount":"$15 million","context":"proposed purchase price (cash and KALA stock)"},{"amount":"$12.7 million","context":"Target trailing-twelve-month revenue ended August 2026 (unaudited)"},{"amount":"$48 million","context":"Target cumulative sales since inception"}]},"materialImpact":{"score":3,"reasoning":"Proposed $15 million acquisition of a cash-flow-positive telehealth platform generating ~$12.7M TTM revenue would be transformative relative to KALA's size, but the LOI is non-binding, financials are unaudited and management-provided, and closing is subject to diligence, stockholder/exchange approvals and license transfers."},"tickerRelevance":{"others":[],"primary":"KALA"},"globalImportance":25,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","riskOverlay":"going-concern and regulatory risk language in same release","eventGravity":"non-binding M&A LOI, transformative relative to micro-cap size","issuerAuthored":true,"dealValueContext":"$15M deal vs sub-$50M-cap issuer"}},"event_type":"m_and_a","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"KALA Bio signed a non-binding LOI to acquire 100% of a U.S.-based MSO supporting a 50-state telehealth platform for approximately $15 million in cash and stock.\n\nThe Target generated about $12.7 million in trailing-twelve-month revenue through August 2026, is cash-flow positive, and has served more than 90,000 clients since 2023, focused on GLP-1 weight management, hormone health, longevity and sexual wellness.\n\nA 45-day diligence period concludes in November 2026, with definitive agreements and closing targeted for late 2026 or early 2027; the deal faces stockholder, Nasdaq and pharmacy-license approvals.\n\nKALA sees the Target as a direct-to-consumer channel for its Virotek genetic testing and a fit with its Researgency.ai platform, but the Target's financials are unaudited and management-provided.","key_figures":{"dealValueUsd":"$15 million","customDimensions":{"target_founded":"2023","target_ttm_revenue":"$12.7 million (TTM ended August 2026, unaudited)","due_diligence_period":"45 days, expected to conclude November 2026","target_clients_served":"more than 90,000","target_sales_since_inception":"over $48 million"}},"named_entities":{"people":[{"name":"Avi Minkowitz","role":"CEO and CFO of KALA Bio"}],"products":["Researgency.ai","GLP-1 compounded therapies","Virotek ophthalmology genetic testing","MSC-S platform"],"companies":[{"name":"KALA Bio, Inc.","ticker":"KALA","relationship":"acquirer"},{"name":"Virotek","relationship":"distribution partner"},{"name":"Younet","relationship":"licensor of Researgency AI platform"}],"dollarAmounts":[{"amount":"$15 million","context":"proposed purchase price (cash and KALA stock)"},{"amount":"$12.7 million","context":"Target trailing-twelve-month revenue ended August 2026 (unaudited)"},{"amount":"$48 million","context":"Target cumulative sales since inception"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T11:30:24.490Z","global_importance":25,"audience_relevance":20,"importance_components":{"tickerTier":"micro-cap","riskOverlay":"going-concern and regulatory risk language in same release","eventGravity":"non-binding M&A LOI, transformative relative to micro-cap size","issuerAuthored":true,"dealValueContext":"$15M deal vs sub-$50M-cap issuer"}},"durationMs":8773,"modelName":"glm-5.3-flashx"}}